Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Acta Oncol. 2010 Aug;49(6):757-66. doi: 10.3109/0284186X.2010.485209.
Cancer prevention clinical trials seek to enroll individuals at increased risk for cancer. Little is known about attitudes among physicians and at-risk individuals towards cancer prevention clinical trials. We sought to characterize barriers to prevention trial participation among medical oncologists and first-degree relatives of their patients.
Physician participants were practicing oncologists in Pennsylvania. Eligible first-degree participants were adult relatives of a cancer patient being treated by one of the study physicians. The influence of perceived psychosocial and practical barriers on level of willingness to participate in cancer prevention clinical trials was investigated.
Response rate was low among physicians, 137/478 (29%), and modest among eligible first-degree relatives, 82/129 (64%). Lack of access to an eligible population for prevention clinical trials was the most commonly cited barrier to prevention clinical trials among oncologists. Nearly half (45%) of first-degree relatives had not heard of cancer prevention clinical trials, but 68% expressed interest in learning more, and 55% expressed willingness to participate. In the proportional odds model, greater information source seeking/responsiveness (i.e., interest in learning more about clinical prevention trials from more information sources) (p = 0.04), and having fewer psychosocial barriers (p = 0.02) were associated with a greater willingness to participate.
Many individuals who may be at greater risk for developing cancer because of having a first-degree relative with cancer are unaware of the availability of clinical cancer prevention trials. Nonetheless, many perceive low personal risk associated with these studies, and are interested in learning more.
癌症预防临床试验旨在招募癌症风险增加的个体。人们对医生和高危个体对癌症预防临床试验的态度知之甚少。我们试图描述医学肿瘤学家和患者的一级亲属参与预防试验的障碍。
研究参与者是宾夕法尼亚州的执业肿瘤学家。合格的一级参与者是正在接受研究医生之一治疗的癌症患者的成年亲属。研究调查了感知的心理社会和实际障碍对参与癌症预防临床试验的意愿水平的影响。
医生的回应率很低,为 137/478(29%),合格的一级亲属的回应率适中,为 82/129(64%)。缺乏可用于预防临床试验的合格人群是肿瘤学家最常提到的预防临床试验障碍。近一半(45%)的一级亲属从未听说过癌症预防临床试验,但 68%的人表示有兴趣了解更多,55%的人表示愿意参与。在比例优势模型中,更多的信息源寻求/响应性(即,更有兴趣从更多信息源了解临床预防试验)(p=0.04),以及较少的心理社会障碍(p=0.02)与更高的参与意愿相关。
许多因一级亲属患有癌症而患癌症风险更高的人不知道临床癌症预防试验的可用性。尽管如此,许多人认为这些研究的个人风险较低,并对此感兴趣。